BR112020003292A2 - compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 - Google Patents
compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 Download PDFInfo
- Publication number
- BR112020003292A2 BR112020003292A2 BR112020003292-1A BR112020003292A BR112020003292A2 BR 112020003292 A2 BR112020003292 A2 BR 112020003292A2 BR 112020003292 A BR112020003292 A BR 112020003292A BR 112020003292 A2 BR112020003292 A2 BR 112020003292A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- chosen
- alkoxy
- methoxy
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| US62/546,290 | 2017-08-16 | ||
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020003292A2 true BR112020003292A2 (pt) | 2020-08-18 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020003292-1A BR112020003292A2 (pt) | 2017-08-16 | 2018-08-16 | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11427573B2 (https=) |
| EP (1) | EP3668865A1 (https=) |
| JP (1) | JP7253832B2 (https=) |
| KR (1) | KR102687118B1 (https=) |
| CN (1) | CN111225913B (https=) |
| AU (1) | AU2018317403B2 (https=) |
| BR (1) | BR112020003292A2 (https=) |
| CA (1) | CA3072493A1 (https=) |
| CL (1) | CL2020000360A1 (https=) |
| CO (1) | CO2020002576A2 (https=) |
| EA (1) | EA202090467A1 (https=) |
| IL (1) | IL272575B2 (https=) |
| PE (1) | PE20200756A1 (https=) |
| SG (1) | SG11202001264UA (https=) |
| UA (1) | UA128084C2 (https=) |
| WO (1) | WO2019036534A1 (https=) |
| ZA (1) | ZA202001321B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2019006157A1 (en) | 2017-06-28 | 2019-01-03 | Vanderbilt University | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| JP2025540259A (ja) * | 2022-12-08 | 2025-12-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| MX2009006401A (es) | 2006-12-20 | 2009-06-23 | Nerviano Medical Sciences Srl | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| AU2010208176A1 (en) | 2009-01-28 | 2011-09-15 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2456310A4 (en) | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| JP2013508413A (ja) | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| KR20120115252A (ko) | 2009-11-06 | 2012-10-17 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법 |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| MX2012009377A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica. |
| EP2568809A4 (en) | 2010-05-12 | 2013-11-06 | Univ Vanderbilt | HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016115282A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
-
2018
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt active IP Right Grant
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
-
2025
- 2025-05-06 US US19/200,356 patent/US20260070897A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020000360A1 (es) | 2020-07-31 |
| AU2018317403A1 (en) | 2020-03-12 |
| CN111225913B (zh) | 2024-05-31 |
| CO2020002576A2 (es) | 2020-04-01 |
| JP2020531454A (ja) | 2020-11-05 |
| EP3668865A1 (en) | 2020-06-24 |
| US11427573B2 (en) | 2022-08-30 |
| ZA202001321B (en) | 2023-10-25 |
| UA128084C2 (uk) | 2024-04-03 |
| SG11202001264UA (en) | 2020-03-30 |
| WO2019036534A1 (en) | 2019-02-21 |
| US20200291019A1 (en) | 2020-09-17 |
| CN111225913A (zh) | 2020-06-02 |
| EA202090467A1 (ru) | 2020-06-18 |
| KR20200054204A (ko) | 2020-05-19 |
| US20190055225A1 (en) | 2019-02-21 |
| US12291521B2 (en) | 2025-05-06 |
| IL272575A (en) | 2020-03-31 |
| IL272575B1 (en) | 2023-05-01 |
| US20220259190A1 (en) | 2022-08-18 |
| US20260070897A1 (en) | 2026-03-12 |
| US10508105B2 (en) | 2019-12-17 |
| CA3072493A1 (en) | 2019-02-21 |
| KR102687118B1 (ko) | 2024-07-19 |
| JP7253832B2 (ja) | 2023-04-07 |
| IL272575B2 (en) | 2023-09-01 |
| PE20200756A1 (es) | 2020-07-27 |
| AU2018317403B2 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020003292A2 (pt) | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 | |
| JP5883399B2 (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 | |
| US9180192B2 (en) | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10294222B2 (en) | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10221172B2 (en) | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EP2533642A1 (en) | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | |
| MX2012009381A (es) | Metodos y sistema para retirar componentes del gas a partir de los gases de proceso. | |
| EP2568809A1 (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| MX2012005248A (es) | Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica. | |
| US11242342B2 (en) | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10968227B2 (en) | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| WO2019006157A1 (en) | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EA043291B1 (ru) | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2018, OBSERVADAS AS CONDICOES LEGAIS |